MLN4924 and Neddylation: Targeting UBE2F-SAG Axis in Tumorigenesis

Introduction

The post-translational modification of proteins by ubiquitin-like molecules is a cornerstone of cellular regulation, particularly in cancer biology. Among these modifications, neddylation—the covalent conjugation of NEDD8 to substrate proteins—has emerged as a critical regulator of protein stability, cell cycle progression, and signal transduction. The neddylation pathway is orchestrated by a cascade of enzymes, including the NEDD8-activating enzyme (NAE), NEDD8-conjugating E2 enzymes (notably UBE2M and UBE2F), and E3 ligases (such as RBX1 and SAG). Dysregulation of neddylation has been implicated in a variety of human diseases, particularly solid tumors. In this context, the selective NAE inhibitor for cancer research, MLN4924, has become an invaluable tool for dissecting the molecular underpinnings of the neddylation pathway and its therapeutic potential.

MLN4924: Mechanism of Action and Biochemical Properties

MLN4924 is a potent and selective NEDD8-activating enzyme inhibitor, with an IC₅₀ of 4 nM against NAE. This small molecule acts by competitively binding to the nucleotide-binding site of NAE, effectively blocking the activation of NEDD8. As a result, the formation of Ubc12–NEDD8 thioester and NEDD8–cullin conjugates is diminished, thereby inhibiting cullin-RING ligase (CRL)-mediated ubiquitination and subsequent proteasomal degradation of critical cell cycle regulators such as CDT1. MLN4924 exhibits high selectivity, with markedly reduced activity against related enzymes including UAE, SAE, UBA6, and ATG7, ensuring pathway-specific effects in experimental settings. Its physicochemical profile—solid at room temperature, highly soluble in DMSO and ethanol but insoluble in water—facilitates diverse applications in both in vitro and in vivo models.

The UBE2F-SAG Axis: A Novel Dimension of Neddylation in Cancer Biology

While the canonical role of neddylation in regulating cullin proteins and CRL activity has been extensively studied, recent advances have illuminated the significance of non-cullin substrates. Notably, a recent study by Zhang et al. (EMBO Journal, 2025) delineates the role of the UBE2F-SAG axis in targeting RHEB, a small GTPase and critical activator of mTORC1. The study demonstrates that UBE2F, in cooperation with the E3 ligase SAG, mediates neddylation of RHEB at lysine 169, enhancing its lysosomal localization and GTP-binding capacity. This modification upregulates mTORC1 signaling, driving cell growth, cell cycle progression, and suppression of autophagy in liver tumorigenesis models. These findings extend the functional landscape of neddylation beyond CRLs, highlighting its influence on signaling networks central to oncogenic transformation and metabolic regulation.

MLN4924 as a Probe of Non-Cullin Neddylation Pathways

The discovery of RHEB as a neddylation substrate broadens the utility of MLN4924 in cancer research. While MLN4924's canonical effect is inhibition of CRL ubiquitination, its upstream blockade of NAE activity also impedes neddylation of non-cullin targets such as RHEB. In cellular models, MLN4924 treatment leads to dose-dependent inhibition of NAE, which, in turn, disrupts the UBE2F-SAG-mediated modification of RHEB. This results in attenuated mTORC1 signaling, decreased cell proliferation, and increased autophagy—phenotypes mirrored by genetic ablation of UBE2F in the Zhang et al. study. The ability of MLN4924 to modulate both canonical (cullin-dependent) and non-canonical (e.g., RHEB) neddylation events positions it as a versatile chemical probe for dissecting the multifaceted roles of neddylation in tumorigenesis.

Implications for Solid Tumor Models and Anti-Cancer Therapeutic Development

In vivo, MLN4924 has demonstrated robust anti-tumor activity in various solid tumor models, including HCT-116 colon carcinoma, H522 lung tumor, and Calu-6 lung carcinoma xenografts. Subcutaneous administration at doses of 30–60 mg/kg significantly inhibits tumor growth with minimal systemic toxicity, as evidenced by stable body weight in treated animals. These effects are attributable to the compound's ability to disrupt CRL-mediated degradation of cell cycle regulators and, as emerging evidence suggests, to perturb mTORC1 signaling via interference with RHEB neddylation. The intersection of these pathways underscores the promise of MLN4924 not only as a research tool but also as a prototype for next-generation anti-cancer therapeutics targeting the neddylation cascade.

Experimental Considerations and Best Practices

For rigorous investigation of neddylation pathway inhibition, careful attention to compound handling and experimental design is essential. MLN4924 should be stored at -20°C and freshly prepared in DMSO or ethanol for short-term use to maintain potency. Its insolubility in water necessitates consideration of vehicle effects in cellular and animal studies. Optimal dosing regimens, tailored to specific cell lines or animal models, should be empirically determined. Given its high selectivity for NAE, MLN4924 enables focused interrogation of neddylation-dependent processes, but off-target effects on related ubiquitin-like modifiers should be excluded by appropriate controls. Furthermore, phenotypic readouts—such as accumulation of CDT1, changes in cell cycle distribution, and markers of mTORC1 activity—can provide mechanistic insight into pathway inhibition.

Integration of MLN4924 in Advanced Cancer Research

Recent advances in omics technologies and CRISPR-based genetic models have facilitated the mapping of neddylation substrates and the elucidation of their biological functions. MLN4924, by virtue of its pharmacological action, complements these approaches by enabling temporal and reversible inhibition of the neddylation pathway. In the context of hepatocellular carcinoma and non-alcoholic fatty liver disease, the findings by Zhang et al. (2025) suggest that targeting the UBE2F-SAG axis may attenuate aberrant mTORC1 activity and tumor progression. The correlation between UBE2F expression, mTORC1 activity, and patient survival further highlights the translational relevance of this axis. MLN4924 provides a strategic avenue for preclinical validation of these targets and for exploring combinatorial regimens with mTOR inhibitors or autophagy modulators.

Future Directions: Neddylation Inhibition Beyond CRLs

The expanding repertoire of neddylation substrates—including transcription factors, kinases, and metabolic regulators—invites a reevaluation of MLN4924’s research applications. As studies continue to uncover non-cullin targets and their roles in oncogenic signaling, MLN4924 stands as a critical reagent for probing these networks. In particular, its ability to inhibit RHEB neddylation and thereby modulate mTORC1-dependent metabolic reprogramming may inform the design of therapies for malignancies characterized by mTOR pathway hyperactivation. Further exploration of MLN4924 analogs with refined selectivity or improved pharmacokinetics could enhance its utility in both basic and translational cancer research.

Conclusion

MLN4924, as a selective NEDD8-activating enzyme inhibitor, has transformed the study of neddylation in cancer biology. By impeding both CRL-mediated ubiquitination and non-cullin substrate modification, it enables detailed mechanistic investigations and supports the development of novel anti-cancer strategies. The recent identification of the UBE2F-SAG-RHEB-mTORC1 axis as a driver of tumorigenesis, and the capacity of MLN4924 to disrupt this pathway, underscore its continued relevance in solid tumor models and anti-cancer therapeutic development. As the field advances, MLN4924 will remain integral to efforts aimed at elucidating the full spectrum of neddylation-dependent processes in health and disease.

Contrast with Existing Literature

While previous articles such as "MLN4924: Selective NAE Inhibitor Targeting Neddylation in..." have thoroughly reviewed the role of MLN4924 in cullin-RING ligase ubiquitination inhibition and established its value in cancer biology research, this article uniquely emphasizes the non-cullin dimensions of neddylation, specifically the UBE2F-SAG-RHEB axis and its implications for mTORC1-driven tumorigenesis. By integrating recent mechanistic insights and focusing on the intersection of neddylation and mTOR signaling, this work provides a distinct and forward-looking perspective on the evolving research applications of MLN4924.